Better monitoring of “early access” patients
The French National Authority for Health defines early access as a system that enables patients who have reached a therapeutic impasse to benefit, on an exceptional and temporary basis, from certain drugs that are not authorized for a specific therapeutic indication. To this end, a certain amount of data (patient characteristics, treatment efficacy, quality of […]